Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00279487 · ClinicalTrials.gov registry record · NA

Preanalgesic Effect of Gabapentin in Total Knee Repair

A NA study, sponsored by Texas Health Resources.

Completed
Registry status
NA
Development phase
24
Enrollment target

NCT00279487: Completed NA study, sponsored by Texas Health Resources.

NCT00279487 is a NA study that has completed, run by Texas Health Resources. The registered enrollment target is 24 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00279487, a NA study, has completed, sponsored by Texas Health Resources.

COMPLETED
Registry status
NA
Development phase
24 participants
Enrollment target

Study Summary

The purpose of this study is to determine whether gabapentin, as a one time administration prior to a total knee replacement procedure, has opioid sparing effects and a reduction in pain scores.

Interventions

  • DRUG Placebos
  • DRUG Gabapentin

Trial Details

FieldValue
Enrollment Target 24 participants
Est. Completion 2007-08
Phase NA
Texas Health Resources

5 total trials

What the finished NCT00279487 record still lists

NCT00279487 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).

The record links to 0 conditions, and to 2 interventions - of which Placebos is the first listed.

NCT00279487 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00279487 about?

NCT00279487 is a clinical study titled "Preanalgesic Effect of Gabapentin in Total Knee Repair". The purpose of this study is to determine whether gabapentin, as a one time administration prior to a total knee replacement procedure, has opioid sparing effects and a reduction in pain scores.

What is the current status of trial NCT00279487?

This trial is currently completed. It is a NA study. The enrollment target is 24 participants. Estimated completion is 2007-08.

What interventions are being tested in trial NCT00279487?

The interventions under investigation include: Placebos (DRUG), Gabapentin (DRUG).

Who is sponsoring clinical trial NCT00279487?

This trial is sponsored by Texas Health Resources, which has 5 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00279487's enrollment target sits among peer trials

24 1736th of 2000 higher than 246 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02331979 · 24 participants · NA

    Improving Bladder Function in SCI by Neuromodulation

  • NCT03096197 · 24 participants · NA

    Exoskeleton and Spinal Cord Stimulation for SCI

  • NCT03223922 · 24 participants · NA

    Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases

  • NCT03326921 · 24 participants · Phase 1

    HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

Source: ClinicalTrials.gov NCT00279487, the US trial registry maintained by the National Library of Medicine. NCT00279487 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.